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Introduction
Helicobacter pylori is a micro-aerophilic, Gram-
negative, spiral-shaped bacterium and its discovery
revolutionised approaches to the pathogenesis and
treatment of peptic ulcer disease.1 The organism is
causally related to chronic active gastritis2; peptic
ulcer disease2; primary low-grade (B-cell) gastric
lymphoma3; and gastric carcinoma.4 Recent epidemi-
ological studies have revealed an association between
H pylori seroprevalence and increasing age,5 lower
socio-economic status,6 and crowding at home.7 A high
H pylori seroprevalence has also been reported in
patients with a range of systemic diseases including
ischaemic heart disease. This is particularly impor-
tant, as H pylori seropositivity can be as high as 60%
in Hong Kong, even in apparently healthy adults.8 If
H pylori does have such pathogenic potential, then its
impact on health care, disease patterns, and the treat-
ment of all the related diseases would be colossal. Most
general readers are confronted with and sometimes
frustrated by an ever-expanding list of conditions
associated with H pylori seropositivity. Accordingly,
this article has been compiled to highlight some of
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the known associations and the scientific basis of
H pylori infections.
The pathogenesis of H pylori infection
Helicobacter pylori is a versatile organism and pro-
duces a range of toxins that are detrimental to gastric
mucosa both in vivo and in vitro.9 These toxic factors
include urease, phospholipase, alcohol dehydrogenase,
vacuolating cytotoxin, haemolysin, platelet activating
factor, and mucolytic factor.9 While the toxins are
undoubtedly harmful to the stomach and duodenum,
they also interact with other tissues in the body. Helico-
bacter pylori has been shown to adhere to several
cell lines derived from different organs of the body.10
The effects of these toxins and their interactions with
gastroduodenal and other tissues are outlined in the
Table.11-18
The presence of H pylori in the gastric mucosa is
almost always associated with mucosal inflammation
due to infiltration by neutrophils and monocytes.19,20
Harmful enzymes such as urease, catalase, protease,
lipase, and phospholipase are produced by H pylori
and may be involved in the pathogenesis of gastric
inflammation.17,21-25 The levels of tumour necrosis
factor (TNF) alpha, interleukin (IL)-1b, and IL-8
are all raised in the gastric mucosa of patients with
H pylori infection compared with those who are not
infected.26 Interleukin-1b is implicated in the recruit-
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ment of circulating neutrophils to sites of inflamma-
tion,27 is a chemoattractant to neutrophils, and stimu-
lates induction of IL-8 in vivo.28 Interleukin-8 is
synthesised by many cells after stimulation by IL-1b,
TNF-α, or endotoxin and is the most potent chemo-
attractant known; it also induces the release of proteases
from neutrophils.29 Helicobacter pylori causes the
release of growth-regulated chemokines, macrophage
inflammatory proteins, and monocyte chemotactic
activating factor, all of which are involved in the
generation of the intense inflammatory reaction that
occurs in gastric mucosa.30
H pylori infection and associated disorders
An increasing number of extragastroduodenal con-
ditions have been related to H pylori infection over
the past decade. The vast majority, if not all, of the
studies have however, employed serological surveil-
lance rather than isolation of H pylori from the target
disease site. This limitation is almost certainly due
to the difficulty in culturing H pylori as well as the
remoteness of some of the target sites, such as the
airway and coronary arteries. Fortunately, serological
testing to indirectly detect H pylori is quick, relatively
cheap, specific, and can be performed using commer-
cially available test kits.
Cardiovascular disorders
At least five studies have investigated the relationship
between H pylori seroprevalence and the risk of
coronary heart disease.31-35 However, whether or not
H pylori infection is associated with an increased risk
for the development of coronary heart disease remains
to be determined. The uncertainty is because these
studies have conflicting results, even when the differ-
ences in their diagnostic criteria of coronary heart
disease have been accounted for. The largest of the
surveys was a case-control study in which controls
showed significantly lower H pylori seropositivity rates
than did men who had had a myocardial infarction
(57% and 70%, respectively; odds ratio [OR]=1.77,
P=0.03).32 But the association between H pylori
seropositivity and myocardial infarction became
insignificant (P=0.40) after adjusting for social class,
residence in high-risk areas, cigarette smoking, high
systolic and diastolic blood pressure, and a lower
1-second forced expiratory volume.32
Although there is still no definitive evidence to
link H pylori infection with coronary heart disease,
various findings support this association. For exam-
ple, H pylori infection has been shown to be associ-
ated with an increase in the level of fibrinogen (after
adjusting for confounding risk factors including age
and smoking).36 In addition, H pylori infection is also
associated with a deterioration in lipid profiles, an event
which could promote atherosclerosis.35 Other disease
mechanisms that have been suggested include the
reduction in the level of antioxidants and the promo-
tion of production of pro-inflammatory mediators.37
Respiratory disorders
Bronchiectasis is a chronic infective and inflamma-
tory disease of the tracheobronchial tree. Affected
patients suffer from recurrent sputum production,
haemoptysis, and bouts of exacerbations. Although
many known causes of bronchiectasis have been iden-
tified, more than 60% of cases have an unknown cause.8
Helicobacter pylori has been recently identified in the
tracheobronchial aspirates of mechanically ventilated
patients and the possibility that H pylori infection might
Table. H pylori exotoxins that potentially have activity at extragastroduodenal sites
Factor produced Source Toxic effect/s Reference
Ammonia H pylori urease Inhibition of protein degradation and vacuolation 11
of lysosomes
Lysolecithin H pylori phosopholipases Cytotoxic compound leading to ulceration 12
Acetaldehyde H pylori alcohol dehydrogenase Denaturation of proteins and induction of lipid 13
peroxidation
Vacuolating 50% of H pylori organisms Vacuolation of eukaryotic cells via unknown 14
cytotoxin mechanisms
Haemolysin H pylori phospholipase? Haemolysis 15
Platelet Unknown Potent inflammatory mediator in various organs 16
activating factor
Mucolytic factor Unknown Degradation of mucin 17
Lipopolysaccharide H pylori cell wall Low biological activity but could inhibit mucin 18
glycosylation
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cause ventilator-associated pneumonia has been
raised.38
There are interesting similarities between the
pathogenesis of bronchiectasis and ulcers. Intense
infiltration of the airway or gastric mucosa with
neutrophils and T lymphocytes,20,39 (mediated by
cytokines, especially IL-8, TNF-α, and IL-1b)40 occurs
in both conditions. Respiratory pathogens such as
Haemophilus influenzae and Pseudomonas aerugi-
nosa persist in the tracheobronchial tree41; similarly,
H pylori can persist within the gastric mucosa for
decades.42 These organisms cause ultrastructural
damage to their target mucosal cells, such as vacuola-
tion and extrusion from the mucosal surface.43-45
Our group has recently reported a high incidence
of H pylori seropositivity in patients with bronchiecta-
sis (76.0%) compared with healthy controls (54.3%;
P=0.001) and patients with tuberculosis (52.9%;
P=0.0001), even after accounting for age, social class,
and household crowdedness.8 The increase in H pylori
seroprevalence appeared to correlate with disease
activity, because the H pylori immunoglobulin (Ig) G
antibody level correlated with sputum production by the
patients with bronchiectasis. The similarities between the
disease process in bronchiectasis and ulceration might
be due to a chronic inflammatory disease or bacteria-
induced tissue damage. It is also possible that aspir-
ation of H pylori or its toxins into the respiratory tract
could occur, particularly given the prevalence of gastro-
oesophageal reflux in patients with bronchiectasis.14
Although asthma is also an inflammatory disease
of the airways and its pathogenesis involves similar
pro-inflammatory mediators as are present in bron-
chiectasis and ulceration, a recent study of asthmatic
patients in Hong Kong showed no association between
asthma and H pylori seropositivity.46
Extragastroduodenal digestive disorders
There have been extensive investigations to find
H pylori seropositivity in other extragastroduodenal
digestive disorders, but despite the volume of work,
proven associations are still few. An association has
been shown between H pylori seropositivity and the
development of hepatic encephalopathy in cirrhotic
patients.47 Another study showed that patients with
pancreatic carcinoma had a H pylori seropositivity
of 65% compared with the controls’ rate of 45%
(OR=2.1).48 However, this study has been partially
discredited because of the lack of controlled data to
eliminate the effects of confounding factors, which are
known to affect H pylori seropositivity.
Other studies have yielded negative results for
associating H pylori seropositivity with a disease state.
Examples of such diseases are recurrent aphthous
stomatitis and other oral disorders,49 inflammatory
bowel disease,50 portal hypertensive gastropathy,51 coe-
liac disease,52 cirrhosis,53 and Barrett’s oesophagitis.54
Neurological disorders
Similar to coronary heart disease, stroke is predom-
inantly related to atherosclerosis of the arteries.
Consequently, investigators have studied the relation-
ship between H pylori infection and cerebrovascular
disease. There are at least two published and well-
designed studies that depict an association between
H pylori seropositivity and cerebrovascular disease.32,55
The more recent and larger study showed H pylori
seropositivity to be 58.8%, while that of the control
group was 44.5% (P=0.01). The odds ratio for cerebro-
vascular disease associated with H pylori seroposi-
tivity of 1.78 was significant, even after adjusting for
confounding factors such as age and social class.55
Growth disorders
Studies have also suggested that an association exists
between small stature and H pylori seropositivity.6,56
One study followed the growth (in height) from age
7 to 11 years in 554 schoolchildren and found
that 11% of them showed evidence of H pylori sero-
positivity by 11 years of age; these children also had
significantly lower heights, even after adjustments had
been made for housing, parental social class, and school
catchment area.6 The growth reduction was largely
confined to girls, among whom height correlated
with salivary IgG values (P=0.05).6 A similar study
performed in Denmark has also shown that H pylori
seropositivity is associated with late menarche.57
The causal linkage of growth retardation to the pres-
ence of inflammatory mediators in those children who
are H pylori–seropositive is purely speculative and
remains to be proven. Further work is clearly neces-
sary to confirm this finding in other ethnic groups and
to determine the underlying mechanism by which
growth retardation occurs during H pylori infection.
Dermatological and autoimmune disorders
Helicobacter pylori seropositivity has been associated
with the presence of rosacea, urticaria, and alopecia
aerata.58,59 Helicobacter pylori seropositivity in Henoch-
Schönlein purpura has also been reported.60 Although
these studies are generally small (eg in the rosacea
study, there were only 31 subjects) and do not have
control group data for comparison, they are parti-
cularly interesting because eradication of H pylori
resulted in improvement of rosacea,58 urticaria,59 and
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Henoch-Schönlein purpura.60 Although these data
and claims of efficacy need to be evaluated by proper
controlled clinical trials, they provide very important
insights into these still largely idiopathic diseases.
There are also other sporadic case reports or small
series which show an association between H pylori
seropositivity and a number of autoimmune disorders
including atrophic thyroiditis,61 Sjögren’s syndrome,62
and idiopathic thrombocytopenia.63 Similar to the
study of bronchiectasis described above,8,40 a study
involving 59 patients with atrophic thyroiditis61
showed that disease activity correlated with the level
of anti–H pylori IgG antibodies present. This suggests
a role for H pylori in the pathogenesis of atrophic
thyroiditis rather than a mere serological association.
Other associated diseases
A handful of small studies suggest an association
between H pylori seropositivity and other diseases.
These include the increased seroprevalence of H pylori
found in individuals affected by Raynaud’s phenomenon
and the fact that eradication therapy improves the
duration and frequency of clinical attacks that patients
experience.64 An association between 143 cases of
diabetes mellitus (45 of them insulin- dependent)
and H pylori seropositivity has been reported; this
observation is independent of age, social class, and
antibiotic treatment.65 In addition, there is also an
association between H pylori seropositivity and head-
ache, including migraine.64,66 Although these studies
are indicative of a possible association, the small
sample size involved and lack of adjustment for con-
founding factors makes it difficult to interpret the data.
Conclusion
The list of diseases that are associated with H pylori
seropositivity is expanding rapidly but has to be inter-
preted with caution, as controlled data are not always
available. This is compounded by the difficulty in ex-
cluding other confounding factors such as age, social
class, household crowdedness, residence in a devel-
oping country (where H pylori infection is pandemic),
other associated diseases, and yet still unknown fac-
tors. The pandemic nature of H pylori seroprevalence
suggests that even if the organism plays a role in the
pathogenesis of so many diseases, it might only be
acting as a cofactor. Basic scientific research to deter-
mine whether or not there is conclusive evidence to
link the pathogenesis of diseases with the presence of
H pylori should be performed. Clinicians and research-
ers will and should undoubtedly pursue these exciting
developments in basic and clinical research.
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